Markets
Stocks
Mutual Funds & ETFs
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Biogen Idec, Inc.
(NQ:
BIIB
)
284.17
USD
-1.65 (-0.58%)
Streaming Delayed Price
/ Updated:
11:41 AM EST, Dec 5, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
304,688
Open
284.95
Bid (Size)
284.22 (400)
Ask (Size)
284.74 (100)
Prev. Close
285.82
Today's Range
283.21 - 288.73
52wk Range
139.72 - 298.82
Shares Outstanding
236,212,930
Dividend Yield
N/A
Performance
YTD
+89.45%
+89.45%
1 Month
+18.37%
+18.37%
3 Month
+28.13%
+28.13%
6 Month
+29.32%
+29.32%
1 Year
+87.13%
+87.13%
Top News
More News
The New England Journal of Medicine publishes pivotal data demonstrating prophylactic infusions of Alprolix(TM) effectively controlled bleeding in haemophilia B patients
Today 2:00 EST
from
GlobeNewswire News Releases
The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX™ Effectively Controlled Bleeding in Hemophilia B Patients
December 04, 2013
from
Business Wire News Releases
More News
Read More
Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting
December 03, 2013
from
Business Wire News Releases
Biogen, Sobi Announce Publication of Phase 3 ALPROLIXTM Haemophilia B Study Data in NEJM
Today 5:59 EST
category
Management
,
Benzinga
,
Global
, and 7 more.
from
Latest Articles from Benzinga.com
Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™
December 02, 2013
from
Business Wire News Releases
Marketing Rights Acquisitions, PDUFA Date Extensions, Accountable Care Relationship and Stock Price Updates - Research Report on Forest Laboratories, Biogen, Bristol-Myers, Express Scripts, and Aetna
Today 8:00 EST
from
PR Newswire
IBB, BIIB, CELG, REGN: Large Outflows Detected at ETF
December 04, 2013
category
ETFs
from
ETF Channel
Biogen Idec Shares Up 17.1% Since SmarTrend's Buy Recommendation (BIIB)
December 04, 2013
from
Comtex SmarTrend® News Briefs
Biogen to Present New Data from Hemphilia Clinical Development, Research Programs
December 03, 2013
category
Benzinga
,
US09062X1037
,
News
, and 1 more.
from
Latest Articles from Benzinga.com
Biogen Idec Inc(BIIB): Biotech, Banks Looks Best on Market Dip
December 03, 2013
category
NYSE:GS
,
NASDAQ:GOOG
,
NASDAQ:FB
, and 13 more.
from
ETF DAILY NEWS
Biogen says FDA extending review of hemophilia drug
December 02, 2013
category
companyNews
from
Reuters: Company News
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here